약물유전체학 시장(2025-2029년)

The global pharmacogenomics market is forecasted to grow by USD 2454.0 mn during 2024-2029, accelerating at a CAGR of 6.5% during the forecast period. The report on the global pharmacogenomics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by imperative of personalized medicine, escalating burden of chronic diseases, accelerating technological advancements in genomics and bioinformatics.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.

Technavio's global pharmacogenomics market is segmented as below:

By End-User

• Hospitals and clinics
• Research organizations
• Academic

By Application

• Oncology
• Drug discovery
• Pain management
• Neurology
• Others

By Technology

• Polymerase chain reaction
• DNA sequencing
• Mass spectrometry
• Microarray
• Electrophoresis

Geography

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
• Asia
• Rest of World (ROW)
• Rest of World (ROW)

This study identifies the integration of artificial intelligence and machine learning as one of the prime reasons driving the global pharmacogenomics market growth during the next few years. Also, evolving regulatory landscape and increased clinical implementation and strategic partnerships and expansion into new therapeutic areas will lead to sizable demand in the market.

The report on the global pharmacogenomics market covers the following areas:

• Global pharmacogenomics market sizing
• Global pharmacogenomics market forecast
• Global pharmacogenomics market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading global pharmacogenomics market vendors that include Abbott Laboratories, Admera Health, Agilent Technologies Inc., Bayer AG, Bio Rad Laboratories Inc., Charles River Laboratories, Danaher Corp., Eurofins Scientific SE, F. Hoffmann La Roche Ltd., GE Healthcare Technologies, geneOmbio Technologies Pvt. Ltd., Illumina Inc., Laboratory Corp., Merck and Co. Inc., Myriad Genetics Inc., OneOme LLC, QIAGEN N.V., Regeneron Pharmaceuticals Inc., Thermo Fisher Scientific Inc.. Also, the global pharmacogenomics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary

• 1.1 Market overview
  • Executive Summary - Chart on Market Overview
  • Executive Summary - Data Table on Market Overview
  • Executive Summary - Chart on Global Market Characteristics
  • Executive Summary - Chart on Market by Geography
  • Executive Summary - Chart on Market Segmentation by End-user
  • Executive Summary - Chart on Market Segmentation by Application
  • Executive Summary - Chart on Market Segmentation by Technology
  • Executive Summary - Chart on Incremental Growth
  • Executive Summary - Data Table on Incremental Growth
  • Executive Summary - Chart on Company Market Positioning

2 Technavio Analysis

• 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• 2.2 Criticality of inputs and Factors of differentiation
• 2.3 Factors of disruption
• 2.4 Impact of drivers and challenges

3 Market Landscape

• 3.1 Market ecosystem
• 3.2 Market characteristics
• 3.3 Value chain analysis

4 Market Sizing

• 4.1 Market definition
• 4.2 Market segment analysis
  • Market segments
• 4.3 Market size 2024
• 4.4 Market outlook: Forecast for 2024-2029

5 Historic Market Size

• 5.1 Global Pharmacogenomics Market 2019 - 2023
  • Historic Market Size - Data Table on Global Pharmacogenomics Market 2019 - 2023 ($ million)
• 5.2 End-user segment analysis 2019 - 2023
  • Historic Market Size - End-user Segment 2019 - 2023 ($ million)
• 5.3 Application segment analysis 2019 - 2023
  • Historic Market Size - Application Segment 2019 - 2023 ($ million)
• 5.4 Technology segment analysis 2019 - 2023
  • Historic Market Size - Technology Segment 2019 - 2023 ($ million)
• 5.5 Geography segment analysis 2019 - 2023
  • Historic Market Size - Geography Segment 2019 - 2023 ($ million)
• 5.6 Country segment analysis 2019 - 2023
  • Historic Market Size - Country Segment 2019 - 2023 ($ million)

6 Qualitative Analysis

• 6.1 Impact of AI on Global Pharmacogenomics Market

7 Five Forces Analysis

• 7.1 Five forces summary
  • Five forces analysis - Comparison between 2024 and 2029
• 7.2 Bargaining power of buyers
  • Bargaining power of buyers - Impact of key factors 2024 and 2029
• 7.3 Bargaining power of suppliers
  • Bargaining power of suppliers - Impact of key factors in 2024 and 2029
• 7.4 Threat of new entrants
  • Threat of new entrants - Impact of key factors in 2024 and 2029
• 7.5 Threat of substitutes
  • Threat of substitutes - Impact of key factors in 2024 and 2029
• 7.6 Threat of rivalry
  • Threat of rivalry - Impact of key factors in 2024 and 2029
• 7.7 Market condition

8 Market Segmentation by End-user

• 8.1 Market segments
• 8.2 Comparison by End-user
• 8.3 Hospitals and clinics - Market size and forecast 2024-2029
• 8.4 Research organizations - Market size and forecast 2024-2029
• 8.5 Academic - Market size and forecast 2024-2029
• 8.6 Market opportunity by End-user
  • Market opportunity by End-user ($ million)

9 Market Segmentation by Application

• 9.1 Market segments
• 9.2 Comparison by Application
• 9.3 Oncology - Market size and forecast 2024-2029
• 9.4 Drug discovery - Market size and forecast 2024-2029
• 9.5 Pain management - Market size and forecast 2024-2029
• 9.6 Neurology - Market size and forecast 2024-2029
• 9.7 Others - Market size and forecast 2024-2029
• 9.8 Market opportunity by Application
  • Market opportunity by Application ($ million)

10 Market Segmentation by Technology

• 10.1 Market segments
• 10.2 Comparison by Technology
• 10.3 Polymerase chain reaction - Market size and forecast 2024-2029
• 10.4 DNA sequencing - Market size and forecast 2024-2029
• 10.5 Mass spectrometry - Market size and forecast 2024-2029
• 10.6 Microarray - Market size and forecast 2024-2029
• 10.7 Electrophoresis - Market size and forecast 2024-2029
• 10.8 Market opportunity by Technology
  • Market opportunity by Technology ($ million)

11 Customer Landscape

• 11.1 Customer landscape overview
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

12 Geographic Landscape

• 12.1 Geographic segmentation
• 12.2 Geographic comparison
• 12.3 North America - Market size and forecast 2024-2029
  • 12.3.1 US - Market size and forecast 2024-2029
  • 12.3.2 Canada - Market size and forecast 2024-2029
  • 12.3.3 Mexico - Market size and forecast 2024-2029
• 12.4 Europe - Market size and forecast 2024-2029
  • 12.4.1 Germany - Market size and forecast 2024-2029
  • 12.4.2 UK - Market size and forecast 2024-2029
  • 12.4.3 France - Market size and forecast 2024-2029
  • 12.4.4 Italy - Market size and forecast 2024-2029
  • 12.4.5 Spain - Market size and forecast 2024-2029
  • 12.4.6 The Netherlands - Market size and forecast 2024-2029
  • 12.4.7 Sweden - Market size and forecast 2024-2029
• 12.5 Asia - Market size and forecast 2024-2029
  • 12.5.1 China - Market size and forecast 2024-2029
  • 12.5.2 Japan - Market size and forecast 2024-2029
  • 12.5.3 India - Market size and forecast 2024-2029
  • 12.5.4 South Korea - Market size and forecast 2024-2029
  • 12.5.5 Singapore - Market size and forecast 2024-2029
  • 12.5.6 Taiwan - Market size and forecast 2024-2029
  • 12.5.7 Indonesia - Market size and forecast 2024-2029
• 12.6 Rest of World (ROW) - Market size and forecast 2024-2029
  • 12.6.1 Brazil - Market size and forecast 2024-2029
  • 12.6.2 South Africa - Market size and forecast 2024-2029
  • 12.6.3 Saudi Arabia - Market size and forecast 2024-2029
  • 12.6.4 UAE - Market size and forecast 2024-2029
  • 12.6.5 Argentina - Market size and forecast 2024-2029
  • 12.6.6 Turkey - Market size and forecast 2024-2029
• 12.7 Market opportunity by geography
  • Market opportunity by geography ($ million)
  • Data Tables on Market opportunity by geography ($ million)

13 Drivers, Challenges, and Opportunity

• 13.1 Market drivers
  • Imperative of personalized medicine
  • Escalating burden of chronic diseases
  • Accelerating technological advancements in genomics and bioinformatics
• 13.2 Market challenges
  • Reimbursement and demonstration of cost-effectiveness
  • Clinical implementation, education, and standardization
  • Ethical, legal, and social issues including regulatory oversight and data privacy
• 13.3 Impact of drivers and challenges
  • Impact of drivers and challenges in 2024 and 2029
• 13.4 Market opportunities
  • Integration of artificial intelligence and machine learning
  • Evolving regulatory landscape and increased clinical implementation
  • Strategic partnerships and expansion into new therapeutic areas

14 Competitive Landscape

• 14.1 Overview
• 14.2 Competitive Landscape
  • Overview on criticality of inputs and factors of differentiation
• 14.3 Landscape disruption
  • Overview on factors of disruption
• 14.4 Industry risks
  • Impact of key risks on business

15 Competitive Analysis

• 15.1 Companies profiled
  • Companies covered
• 15.2 Company ranking index
  • Company ranking index
• 15.3 Market positioning of companies
  • Matrix on companies position and classification
• 15.4 Abbott Laboratories
  • Abbott Laboratories - Overview
  • Abbott Laboratories - Business segments
  • Abbott Laboratories - Key news
  • Abbott Laboratories - Key offerings
  • Abbott Laboratories - Segment focus
  • SWOT
• 15.5 Admera Health
  • Admera Health - Overview
  • Admera Health - Product / Service
  • Admera Health - Key offerings
  • SWOT
• 15.6 Agilent Technologies Inc.
  • Agilent Technologies Inc. - Overview
  • Agilent Technologies Inc. - Business segments
  • Agilent Technologies Inc. - Key news
  • Agilent Technologies Inc. - Key offerings
  • Agilent Technologies Inc. - Segment focus
  • SWOT
• 15.7 Bio Rad Laboratories Inc.
  • Bio Rad Laboratories Inc. - Overview
  • Bio Rad Laboratories Inc. - Business segments
  • Bio Rad Laboratories Inc. - Key news
  • Bio Rad Laboratories Inc. - Key offerings
  • Bio Rad Laboratories Inc. - Segment focus
  • SWOT
• 15.8 Charles River Laboratories
  • Charles River Laboratories - Overview
  • Charles River Laboratories - Business segments
  • Charles River Laboratories - Key offerings
  • Charles River Laboratories - Segment focus
  • SWOT
• 15.9 Danaher Corp.
  • Danaher Corp. - Overview
  • Danaher Corp. - Business segments
  • Danaher Corp. - Key news
  • Danaher Corp. - Key offerings
  • Danaher Corp. - Segment focus
  • SWOT
• 15.10 Eurofins Scientific SE
  • Eurofins Scientific SE - Overview
  • Eurofins Scientific SE - Business segments
  • Eurofins Scientific SE - Key offerings
  • Eurofins Scientific SE - Segment focus
  • SWOT
• 15.11 F. Hoffmann La Roche Ltd.
  • F. Hoffmann La Roche Ltd. - Overview
  • F. Hoffmann La Roche Ltd. - Business segments
  • F. Hoffmann La Roche Ltd. - Key news
  • F. Hoffmann La Roche Ltd. - Key offerings
  • F. Hoffmann La Roche Ltd. - Segment focus
  • SWOT
• 15.12 Illumina Inc.
  • Illumina Inc. - Overview
  • Illumina Inc. - Business segments
  • Illumina Inc. - Key news
  • Illumina Inc. - Key offerings
  • Illumina Inc. - Segment focus
  • SWOT
• 15.13 Laboratory Corp.
  • Laboratory Corp. - Overview
  • Laboratory Corp. - Business segments
  • Laboratory Corp. - Key news
  • Laboratory Corp. - Key offerings
  • Laboratory Corp. - Segment focus
  • SWOT
• 15.14 Myriad Genetics Inc.
  • Myriad Genetics Inc. - Overview
  • Myriad Genetics Inc. - Product / Service
  • Myriad Genetics Inc. - Key news
  • Myriad Genetics Inc. - Key offerings
  • SWOT
• 15.15 OneOme LLC
  • OneOme LLC - Overview
  • OneOme LLC - Product / Service
  • OneOme LLC - Key offerings
  • SWOT
• 15.16 QIAGEN N.V.
  • QIAGEN N.V. - Overview
  • QIAGEN N.V. - Product / Service
  • QIAGEN N.V. - Key news
  • QIAGEN N.V. - Key offerings
  • SWOT
• 15.17 Regeneron Pharmaceuticals Inc.
  • Regeneron Pharmaceuticals Inc. - Overview
  • Regeneron Pharmaceuticals Inc. - Product / Service
  • Regeneron Pharmaceuticals Inc. - Key offerings
  • SWOT
• 15.18 Thermo Fisher Scientific Inc.
  • Thermo Fisher Scientific Inc. - Overview
  • Thermo Fisher Scientific Inc. - Business segments
  • Thermo Fisher Scientific Inc. - Key news
  • Thermo Fisher Scientific Inc. - Key offerings
  • Thermo Fisher Scientific Inc. - Segment focus
  • SWOT

16 Appendix

• 16.1 Scope of the report
  • Market definition
  • Objectives
  • Notes and caveats
• 16.2 Inclusions and exclusions checklist
  • Inclusions checklist
  • Exclusions checklist
• 16.3 Currency conversion rates for US$
  • Currency conversion rates for US$
• 16.4 Research methodology
  • Research methodology
• 16.5 Data procurement
  • Information sources
• 16.6 Data validation
  • Data validation
• 16.7 Validation techniques employed for market sizing
  • Validation techniques employed for market sizing
• 16.8 Data synthesis
  • Data synthesis
• 16.9 360 degree market analysis
  • 360 degree market analysis
• 16.10 List of abbreviations
  • List of abbreviations